Gilead Sciences

News

Gilead's twice-yearly PrEP drug is cleared by FDA

Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?

News

ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC

Gilead lays down a marker for AZ and Daiichi Sankyo to follow as Trodelvy scores in first-line treatment of triple-negative breast cancer (TNBC).

News

Gilead Sciences' chief executive Daniel O'Day

Gilead ups its US investment plans by $11 billion

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US.

News

Women & HIV ambassador, Iris, on a block 'I' in 'HIV'

UK's HIV response is 'failing women'

Women are being overlooked in the UK's HIV response and can face barriers to accessing prevention, testing and care, says a new campaign.

News

Vials on a conveyor belt - pharma manufacturing

Trodelvy-Keytruda pairing hits the spot in breast cancer

Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda.

Patients

How pharma is tackling new direct-to-patient programmes

At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.

Gilead's twice-yearly PrEP drug is cleared by FDA

ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC

Gilead ups its US investment plans by $11 billion

UK's HIV response is 'failing women'

Trodelvy-Keytruda pairing hits the spot in breast cancer

How pharma is tackling new direct-to-patient programmes

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

Gilead Sciences

Editor's Picks